Akèy › Skleroderm Difize › New York
Etid klinik pou Skleroderm Difize nan New York
9 etid pou Skleroderm Difize ap chèche patisipan nan sit nan New York.
Vil nan New York
Tèks ofisyèl etid la (Anglè)
A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis
- Hospital for Special Surgery, New York
Ap rekriteFaz 2
Laj 18 a 70 · Tout sèks · Mizajou Sep 28, 2026 · NCT06470048EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
- NYU Langone Health, Brooklyn
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT07287670A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
- Icahn School of Medicine at Mount Sinai, New York
Ap rekriteFaz 1
Laj 18 a 74 · Tout sèks · Mizajou Sep 10, 2026 · NCT07085104A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)
- GSK Investigational Site, New York
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT06716606A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
- GSK Investigational Site, New York
- GSK Investigational Site, New York
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Sep 8, 2026 · NCT05878717Platform Clinical Study for Conquering Scleroderma
- Northwell Health, Great Neck
- Hospital for Special Surgery, New York
- Columbia University Medical Center, New York
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 18, 2026 · NCT06195072RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
- Columbia University Irving Medical Center, New York
- University of Rochester, Rochester
Ap rekriteFaz 2/3
Laj 18 a 75 · Tout sèks · Mizajou Aug 17, 2026 · NCT06328777A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
- Nkarta Investigational Site, New York
- Nkarta Investigational Site, Stony Brook
- Nkarta Investigational Site, Syracuse
Ap rekriteFaz 1/2
Laj 18 a 75 · Tout sèks · Mizajou Aug 7, 2026 · NCT06733935Scleroderma Registry & Repository at the Hospital for Special Surgery
- Hospital for Special Surgery, New York
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 18 ak plis · Tout sèks · Mizajou Nov 26, 2025 · NCT01656447Sous ClinicalTrials.gov, done yo ranmase Oct 2, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.